Last reviewed · How we verify
Levocetirizine plus Hydroxyzine
This combination blocks histamine H1 receptors to reduce allergic symptoms and itching.
This combination blocks histamine H1 receptors to reduce allergic symptoms and itching. Used for Allergic rhinitis, Urticaria, Pruritus and allergic dermatitis.
At a glance
| Generic name | Levocetirizine plus Hydroxyzine |
|---|---|
| Also known as | Xyzal plus Atarax |
| Sponsor | Association Asthma, Bulgaria |
| Drug class | H1-receptor antagonist combination |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Levocetirizine is a selective H1-receptor antagonist that crosses the blood-brain barrier minimally, reducing histamine-mediated allergic responses. Hydroxyzine is a first-generation antihistamine with additional anxiolytic and anticholinergic properties. Together, they provide complementary antihistamine coverage for allergic conditions.
Approved indications
- Allergic rhinitis
- Urticaria
- Pruritus and allergic dermatitis
Common side effects
- Drowsiness
- Dry mouth
- Headache
- Fatigue
Key clinical trials
- Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses (PHASE4)
- Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levocetirizine plus Hydroxyzine CI brief — competitive landscape report
- Levocetirizine plus Hydroxyzine updates RSS · CI watch RSS
- Association Asthma, Bulgaria portfolio CI